NYSE:EMA eMagin (EMA) Stock Price, News & Analysis → Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad) Free EMA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$55.50 Stock AnalysisStock Analysis Get eMagin alerts: Email Address Ad Behind the MarketsTiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>> About eMagin Stock (NYSE:EMA)eMagin Corporation engages in the design, develop, manufacture, and market of organic light-emitting diode (OLED) miniature displays on-silicon micro displays, virtual imaging products that utilize OLED micro displays, and related products in the United States and internationally. It offers super video graphics array (SVGA) + OLED micro displays; digital SVGA OLED-XL; super extended graphics array OLED-XL/XLS; video graphics array OLED-XL; and widescreen ultra-extended graphics array OLED-XL. The company also provides design reference kits, which include a micro display and associated electronics to help original equipment manufacturers (OEMs) to evaluate micro display products; near-eye virtual imaging modules that incorporate its OLED-on-silicon micro displays with its lenses and electronic interfaces for integration into OEM products; prism optics, a molded plastic prism lens that permits its AMOLED micro displays to provide realistic images that can be viewed for extended periods with reduced eye-fatigue; and driver boards. Its products are used in military aviation helmets, military weapons sights and targeting systems, night vision and thermal imaging devices, training and simulation, visualization for ocular surgery, mobile ultrasound, and augmented reality applications. The company was founded in 1996 and is headquartered in Hopewell Junction, New York.Read More Ad Behind the MarketsTiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>> EMA Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive EMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for eMagin and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNYSE SectorComputer and Technology Industry Electronic Components Sub-IndustryN/A Current SymbolNYSE:EMA CUSIPN/A CIKN/A Webemagin.com Phone845 838 7900FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Target$55.50 High Stock Price Target$62.00 Low Stock Price Target$49.00 Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key CompetitorsMaris-TechNASDAQ:MTEKWMicroCloud HologramNASDAQ:HOLOWSyntec OpticsNASDAQ:OPTXWTempo AutomationNASDAQ:TMPOWAERWINS TechnologiesNASDAQ:AWINWView All Competitors EMA Stock Analysis - Frequently Asked Questions Should I buy or sell eMagin stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for eMagin in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EMA shares. View EMA analyst ratings or view top-rated stocks. What is eMagin's stock price target for 2024? 2 Wall Street research analysts have issued 1 year target prices for eMagin's stock. Their EMA share price targets range from $49.00 to $62.00. On average, they anticipate the company's stock price to reach $55.50 in the next year. View analysts price targets for EMA or view top-rated stocks among Wall Street analysts. What ETFs hold eMagin's stock? ETFs with the largest weight of eMagin (NYSE:EMA) stock in their portfolio include Timothy Plan Market Neutral ETF (TPMN), Franklin International Low Volatility High Dividend Index ETF (LVHI), SPDR S&P International Dividend ETF (DWX), First Trust S&P International Dividend Aristocrats ETF (FID), SPDR S&P Global Dividend ETF (WDIV), First Trust EIP Carbon Impact ETF (ECLN), iShares Global Utilities ETF (JXI) and JPMorgan BetaBuilders Canada ETF (BBCA). What other stocks do shareholders of eMagin own? Based on aggregate information from My MarketBeat watchlists, some companies that other eMagin investors own include Alibaba Group (BABA), Renaissance IPO ETF (IPO), Johnson & Johnson (JNJ), Tesla (TSLA), Visa (V), Air Canada (AC), Accenture (ACN), Advanced Micro Devices (AMD), AzurRx BioPharma (AZRX). This page (NYSE:EMA) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsBiden’s $374B Giveaway Into This SectorDTIHe Is Giving Away BitcoinCrypto Swap ProfitsSHOCKING Crypto Leak…Crypto 101 MediaThe #1 Crypto for 2024InvestorPlaceHow Biden has already won 2024Porter & CompanyUrgent alert: open this for a huge profit potentialTimothy SykesMy biggest AI fearParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eMagin Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.